Seaport Therapeutics secures US$225 Series B funding to develop neuropsychiatric medicines using Monash University prodrug technology
Posted: 29 October 2024 The clinical-stage biopharmaceutical company, Seaport Therapeutics, which uses a unique drug delivery platform originally developed by Monash University, has announced the closing of an oversubscribed US$225 million Series B financing round. The funding syndicate was…
Monash University co-leads international team to develop innovative new approach to treating stroke
Posted: 29 October 2024 Monash University and Yale University, USA, have together received $4M AUD in funding from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS),…
New Alzheimer’s disease blood test shown to work on widely available pathology equipment
Posted: 29 October 2024 Florey researchers – with Australian research volunteers – have evaluated a new diagnostic blood test for Alzheimer’s and found it to be a reliable measure of the disease’s presence and stage. Plasma pTau217 blood…
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
Posted: 29 October 2024 Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®[1]), an agent for the imaging of glioma. The application has been…
4DMedical Secures $1.9M Grant to Ramp-up Trials for ‘Safer, Cheaper’ Lung Imaging
Posted: 29 October 2024 4DMedical has been awarded $1.9 million from the Federal Government under the latter’s CRC-P (Cooperative Research Centres Projects) grant program to fund its expansion and ramp-up of clinical trials for CT:VQ, being run in…
Investigations into lung cancer and into epigenetics recognised with 2 x $1.25 million CSL Centenary Fellowships
Posted: 29 October 2024 Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. The Fellowships were presented at the Australian Academy of Health and Medical Sciences Annual Meeting on Thursday…
Masterclass agenda – Vital ventures: Scaling healthtech with sustainable strategies
Part A | Tuesday 26 November 2024 BioForum – Biotech scandal to SaaS Success: Fireside chat with Theranos ’survivor’ Marissa Senzaki 03:45 PM Guest arrival and registration
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
Posted: 21 October 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first part (Part A, single dose) of the…
MTPConnect Cements US Medtech Links Through MoU with Influential Medical Alley
Posted: 21 October 2024 MTPConnect, Australia’s life science innovation accelerator, and Medical Alley, headquartered in Minnesota have committed to ongoing collaboration to support the growth of medtech companies with the signing today of a Memorandum of Understanding. The…
$22 million investment in cancer clinical trials to save lives throughout Australia
Posted: 21 October 2024 The Minister for Health and Aged Care, the Hon Mark Butler MP, today announced the successful applicants for the 2024-2027 Support for Cancer Clinical Trials (Clinical Trials) program, with a total of $22.19 million…
Recruitment Restarts in Accent Pancreatic Cancer Trial
Posted: 21 October 2024 Amplia has announced that recruitment of the final cohort of patients in the ACCENT clinical trial has begun with the first patient having started on trial this week. A total of 50 patients are…
South African and Australian health product regulators to share regulatory information and expertise
Posted: 14 October 2024 The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. The MoU…
